GammabeamX200 Preclinical Research Irradiator

GammabeamX200 临床前研究辐照器

• 批准号: 7795491
• 负责人: Silvia C. Formenti
• 金额: $ 46.97万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-15 至 2011-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7795491
• 关键词: Affect; Animals; Area; Basic Science; Cells; Clinical; Collaborations; Communities; DNA Repair; Dose; Environment; Equipment; Excision; Faculty; Funding; Genetic Transcription; Genetic Translation; Hour; Immune; Immune system; Ionizing radiation; Linear Accelerator Radiotherapy Systems; Malignant Neoplasms; Marshal; Medical Research; Messenger RNA; Modern Medicine; Molecular; Molecular Genetics; New York; Operating System; Patients; Peer Review; Productivity; Proteins; Radiation; Radiation Oncology; Radiation therapy; Radiobiology; Recruitment Activity; Research; Research Personnel; Research Project Grants; Scientist; Services; Signal Transduction; Tissues; Universities; Work; cost; cytokine; mRNA Stability; medical schools; pre-clinical; pre-clinical research; programs; repaired; research study; response; tool; tumor

DESCRIPTION (provided by applicant): Only a fraction of the enormous potential of ionizing radiation has been described and understood at molecular and genetic levels, and much of our understanding has not yet been harnessed in modern medicine. We are proposing to acquire a new preclinical irradiator to fulfill the need of multiple peer-reviewed funded users, including eleven NIH-funded investigators who are pioneering a new understanding and new applications for ionizing radiation. This community has developed over the past decade at New York University School of Medicine (NYU). Since the establishment of the Department of Radiation Oncology in 2000, a widespread recognition of the multi-dimensional uses of radiation as a tool for research and treatment has occurred. The department has developed collaborations with existing NYU scientists and recruited an outstanding group of new investigators who are at the forefront of understanding the molecular and genetic mechanisms by which ionizing radiation acts on normal and cancer tissues, and affects the normal and cancer tissue micro-environment. At the molecular level, major research areas of the faculty that would benefit and depend on a new irradiator include ionizing radiation alteration of DNA repair, mRNA transcription, mRNA stability, mRNA translation, and protein stability. In addition to more classical radiobiology research, NYU has explored less conventional uses of radiotherapy, such as its capacity to induce "danger signals" to influence the immune system. Original research at the detailed cytokine and immune cell level, with a focus on its applications to stimulate anti-tumor immunological responses, has been pioneered. Currently fourteen distinct teams of investigators from twelve distinct departments are conducting preclinical, translational and basic research on ionizing radiation. The experimental Co60 unit designated in 2000 for animal work has been recently de-commissioned because it is impossible to repair the operating system. To sustain the continuity of NIH-funded research projects and other federally funded projects, a clinical linear accelerator, a Varian Clinac 2100MV (which is also used for patients) has been assigned for after-hours use. Unfortunately, this relegates research studies to evening and late night hours, resulting in increased administrative and overtime operational costs. Moreover, it is not possible to conduct low dose and long duration studies with the Clinac, because of the technical specifications of the equipment. A new experimental irradiator will assure greater productivity and encourage investigators to pursue hypothesis-driven research on the effects and applications of ionizing radiation. A Theratronics Gammabeam X200 (GBX200) Co60 research irradiator is requested, to be installed in our current experimental vault, after removal of the current out-of service machine. The new equipment is essential for maintaining ongoing radiation research programs. NYU SoM is poised to marshal extraordinary research and clinical breadth and expertise to become a pioneering world leader in radiation biology medical research.

描述(申请人提供)：电离辐射的巨大潜力只有一小部分在分子和基因水平上被描述和理解，我们的大部分理解还没有被现代医学利用。我们建议购买一种新的临床前辐射器，以满足多个同行审查的资助用户的需求，其中包括11名由NIH资助的研究人员，他们正在开创对电离辐射的新理解和新应用。这个社区是纽约大学医学院(NYU)在过去十年里发展起来的。自2000年设立放射肿瘤学系以来，人们普遍认识到辐射作为研究和治疗工具的多方面用途。该部门与纽约大学现有的科学家开展了合作，并招募了一批杰出的新调查人员，他们走在了解电离辐射作用于正常组织和癌症组织并影响正常组织和癌症组织微环境的分子和遗传机制的前沿。在分子水平上，教研室将受益于和依赖于新型辐照剂的主要研究领域包括电离辐射对DNA修复、mRNA转录、mRNA稳定性、mRNA翻译和蛋白质稳定性的影响。除了更经典的放射生物学研究外，纽约大学还探索了放射治疗的非常规用途，例如它能够诱导“危险信号”影响免疫系统。在详细的细胞因子和免疫细胞水平上的原创性研究，重点是它在刺激抗肿瘤免疫反应方面的应用，已经是开创性的。目前，来自12个不同部门的14个不同的研究团队正在进行电离辐射的临床前、转化性和基础研究。2000年被指定用于动物工作的实验Co60装置最近被取消使用，因为它不可能修复操作系统。为了维持NIH资助的研究项目和其他联邦资助项目的连续性，一台临床直线加速器--瓦里安诊所2100 MV(也用于患者)已被指定在下班后使用。不幸的是，这使得研究工作只能在晚上和深夜进行，从而增加了行政和加班的运作成本。此外，由于设备的技术规格，不可能用Clinac进行低剂量和长时间的研究。一种新的实验性辐照器将确保更高的生产率，并鼓励研究人员对电离辐射的影响和应用进行假设驱动的研究。在移除当前停止使用的机器后，要求在我们当前的实验库中安装一台Theratronics GammaBeam X200(GBX200)Co60研究辐照器。新设备对维持正在进行的辐射研究计划至关重要。纽约大学Som准备汇集非凡的研究、临床广度和专业知识，成为辐射生物学和医学研究的开创性世界领导者。

项目成果

Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?

• DOI: 10.1016/j.it.2018.03.002
• 发表时间: 2018-06
• 期刊: Trends in immunology
• 影响因子: 16.8
• 作者: Vanpouille-Box C;Formenti SC
• 通讯作者: Formenti SC

Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells.

• DOI: 10.1016/j.xpro.2021.100488
• 发表时间: 2021-06-18
• 期刊: STAR protocols
• 作者: Sato A;Buque A;Yamazaki T;Bloy N;Petroni G;Galluzzi L
• 通讯作者: Galluzzi L